MRMD MariMed Inc.

OTC
$0.06

MariMed Sets a Revenue Record and Holds Its Loss Flat, but Stalled Margins and Slipping Federal Catalysts Cap the Rebound

MariMed reported a loss of $0.01 per share for the third quarter, unchanged from a year ago (EPS growth of 0.0%), on record revenue of $44.23 million, up 8.5% year over year. No consensus estimate was available, so the quarter has to be judged on its trajectory rather than a surprise. On that basis, the top line is clearly improving. Year-over-year growth has stepped up each quarter, from 4.2% in Q1 to roughly 6% in Q2 and 8.5% now. Revenue also rose 5.5% sequentially from $41.9 million. The central tension is that this sales growth is still not becoming profit growth. Adjusted EBITDA rose 18% sequentially to $4.7 million but fell 9% year over year, despite $3.5 million of additional revenue.

The quality of the quarter deserves scrutiny below the EBITDA line. GAAP gross margin slipped to 38.8% from 40.1%. GAAP operating income fell to $1.2 million from $1.6 million. Interest expense climbed to $2.0 million, and a $2.7 million tax provision on a pre-tax loss of $0.7 million widened the GAAP net loss to $3.5 million from $2.9 million. That tax provision reflects the 280E burden that leaves no profit at the bottom line. The balance sheet shows the same burden: income taxes payable have climbed to $34.2 million from $27.0 million at year-end. That $7.2 million increase in unpaid taxes is larger than the entire $6.7 million of nine-month operating cash flow. The record cash balance of $10.4 million is real, but it is being supported by a growing tax liability that bears watching.

The operating story improved in several important ways. Retail revenue of $24.5 million grew 8% year over year, up from 4% in Q2, and transactions grew for a fourth straight quarter. Average order value also turned positive for the first time this year, rising 3% sequentially and 1% year over year after basket compression in Q1 and Q2. Delaware retail rose 26% year over year and Illinois 11%, and loyalty membership is up 31% year to date versus 14% at mid-year. In wholesale, revenue of $19.5 million grew 8% on distribution gains. Doors reached 721, up 13% year over year, and branded share rose 150 basis points. However, volume drove roughly 86% of sequential wholesale growth while realized pricing kept falling, and Massachusetts price compression persists. Cost discipline was the clearest positive. Operating expenses rose only about $130,000 on $2.3 million of incremental sequential revenue, pushing opex to roughly 36% of sales from 38%.

Margins are the weak link, and management was candid about it. Adjusted gross margin has sat at about 40% for four quarters and remains about 140 basis points below last year. Direct materials costs rose $3.2 million amid inflation. In Q2 the CFO called the margin pressure "transitional"; this quarter he said "it's not progress until the line turns up." That is a notably less forgiving framing. There was also no formal Q4 guidance.

The catalyst picture is mixed:

  • **Near-term positives:** Betty's Eddies climbed to the No. 2 edible in Maine, and licensing revenue rose 43% sequentially. The New York licensing deal now covers the full portfolio for a 1H27 launch. Massachusetts Question 8 was defeated, removing a home-state rollback risk, and management cited Illinois' hemp ban as a potential tailwind. Shareholders also authorized a contingent reverse split that could open a path to a major U.S. exchange.
  • **Federal timing slipped:** Last quarter management expected clarity on rescheduling, 280E relief and banking by year-end. It now points to developments after the midterms.
  • **Missing updates:** The call did not address the Columbus, Ohio dispensary, which was slated to contribute "later this year," Pennsylvania licensing, or Massachusetts store expansion.
  • **Competition:** New retail competition near Annapolis adds a fresh risk in Maryland.

Investors were not positioned for good news. Earnings Whispers sentiment stood at a deeply negative -0.81 around the prior report, and no updated reading is available. The stock opened around $0.06 after the August release, slightly below its 200-day moving average near $0.07. That points to a market that has treated MariMed as a sub-dime, catalyst-dependent name rather than rewarding its operating progress. Lower leverage (about 4.4x from 5.2x) and the uplisting option could eventually broaden the shareholder base, but neither changes the earnings math today.

The bottom line is that MariMed delivered its most convincing operating quarter in some time: accelerating revenue, the first positive basket trend, real operating leverage and a stronger cash position. However, the improvement is visible mostly in sequential EBITDA. Year-over-year profitability is still slipping, gross margin has not turned, and per-share earnings are no better than a year ago. With federal tax relief pushed further out and unpaid taxes still piling up, the investment case now rests on whether volume-driven growth can finally lift margins. Until that line turns up, as the CFO put it, bears retain legitimate ammunition.

← Back to MRMD news